All News

Last year saw the first two FDA approvals of oncology biosimilars, but experts have voiced concerns about the emerging US biosimilars market, particularly regarding clinical uptake and uncertainty about costs.

In this slide show we highlight some of the top news from the past year on genetic testing for cancer, including gene signatures for identifying different sub-types of breast cancer, the influence of genetics on RCC outcomes, and the utility of liquid biopsies.

Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.

The largest and most up-to-date study of international cancer registries shows that survival trends are generally increasing, even for some lethal cancers.

The US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults.

Investigators found a methylation-independent loss of MYO5B expression in CRC that matched disease progression, which indicates that the use of MYO5B alone or in combination with its adapter protein RAB8A is a prognostic marker for the disease.

Using a super computer, a team at Brown University has created a model of sickle cell anemia, devising a method that could help researchers assess and evaluate treatments to combat sickle cell disease.

ASCO recently released a clinical practice guideline on the treatment of malignant pleural mesothelioma, including recommendations on diagnosis, staging, and treatment with chemotherapy, surgical cytoreduction, and radiation therapy.

Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.

Here, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.

Last month we asked our readers: If you were to start your career again, would you still choose oncology, would you pick a different specialty, or would you perhaps not choose a career in medicine at all? Here are the results.

This video reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in HR-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.

Learn about what motivational pharmacology is and is not in this quiz.

This video highlights a study on optoacoustic imaging, a new type of imaging that could improve breast cancer diagnosis by differentiating between benign and malignant breast masses.

A new study has shown several ways that the health-related quality of life in cancer patients older than 65 years could be improved.

Experience with the recently enacted California End of Life Option Act has shown that a high percentage of patients who requested aid-in-dying drugs in California have proceeded with ingesting the drugs. The majority of these requests were made by terminal cancer patients.

Survival disparities for black patients with ovarian, colon, and breast cancer and childhood ALL suggest a need for efforts toward improved screening and treatment adherence in this population.

In this interview, we discuss a mathematical model that was created to predict patient response to immunotherapy for cancer treatment.

A recent analysis from the Breast Cancer Surveillance Consortium revealed that community oncology practices are neglecting to use MRI screening for at-risk women, and lower-risk women are being unnecessarily screened.

A new study has found that there are significant gaps in participation among people aged 75 and older in clinical trials of hematologic malignancies when considered against the incidence of these malignancies in this age group.

The needs and challenges of cancer survivors and their family members do not vanish once treatment has been completed, although their follow-up care is often not addressed sufficiently.

This article highlights the typical skin reactions associated with RT, as well as current evidence-based approaches to management and intervention.

In this interview we discuss the goals of SIO, the response to donations intended for interdisciplinary integrative health, and how palliative care and psychosocial oncology can enhance each other.

Patients with gastrointestinal neuroendocrine tumors with carcinoid syndrome are more than twice as likely to have certain pre-existing diagnoses compared with patients without carcinoid syndrome, according to the results of a study.

Patient access to NCI Cancer Centers is influenced by a complex mix of cancer center distribution and density, ethnicity, urbanicity, and travel time to care, according to a recently published statistical model.

Post-traumatic stress disorder may be persistent or worsening in patients with cancer up to 4 years after an initial diagnosis of the disorder, according to the results of a study.

Rolapitant plus 5-HT3 receptor antagonist and dexamethasone is well tolerated and more effectively controls chemotherapy-induced nausea and vomiting compared with 5-HT3 and dexamethasone alone.

Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin.